

Jose Maria Castellano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8915956/publications.pdf>

Version: 2024-02-01

50
papers

2,102
citations

279778

23
h-index

243610

44
g-index

55
all docs

55
docs citations

55
times ranked

3914
citing authors

#	ARTICLE	IF	CITATIONS
1	Barriers and Solutions to Improve Therapeutic Adherence from the Perspective of Primary Care and Hospital-Based Physicians. Patient Preference and Adherence, 2022, Volume 16, 697-707.	1.8	4
2	Prognostic implications of neutrophilâ€lymphocyte ratio in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13404.	3.4	92
3	Risk Score for Predicting In-Hospital Mortality in COVID-19 (RIM Score). Diagnostics, 2021, 11, 596.	2.6	27
4	Hemogram as Marker of In-Hospital Mortality in Covid-19. Journal of Investigative Medicine, 2021, 69, 962-969.	1.6	26
5	Hemogram-derived ratios as prognostic markers of ICU admission in COVID-19. BMC Emergency Medicine, 2021, 21, 89.	1.9	15
6	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1133-1146.	13.7	87
7	Estimation of the major cardiovascular events prevention with Inclisiran. Atherosclerosis, 2020, 313, 76-80.	0.8	19
8	Polypill strategy at the heart of cardiovascular secondary prevention. Heart, 2019, 105, 9-10.	2.9	8
9	Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study. Archives of Medical Research, 2019, 50, 31-40.	3.3	24
10	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. Journal of Cardiac Failure, 2018, 24, 78-86.	1.7	10
11	Putting polypills into practice: challenges and lessons learned. Lancet, The, 2017, 389, 1066-1074.	13.7	68
12	Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the <sc>CAPS</sc> study. Cardiovascular Therapeutics, 2017, 35, e12240.	2.5	12
13	Role of the polypill for secondary prevention in ischaemic heart disease. European Journal of Preventive Cardiology, 2017, 24, 44-51.	1.8	17
14	A 30-month worksite-based lifestyle program to promote cardiovascular health in middle-aged bank employees: Design of the TANSNIP-PESA randomized controlled trial. American Heart Journal, 2017, 184, 121-132.	2.7	22
15	Utilidad de un policomprimido cardiovascular enÂelÂtratamiento deÂpacientes enÂprevenciÃ³n secundaria enÂEspaÃ±a: unÂestudio deÂcoste-efectividad. Revista Espanola De Cardiologia, 2017, 70, 42-49.	1.2	28
16	Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Revista Espanola De Cardiologia (English Ed), 2017, 70, 42-49.	0.6	13
17	Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The ESCARVAL-RISK study. PLoS ONE, 2017, 12, e0186196.	2.5	72
18	Assessing the Impact of MedicationÂAdherence on Long-Term Cardiovascular Outcomes. Journal of the American College of Cardiology, 2016, 68, 789-801.	2.8	208

#	ARTICLE	IF	CITATIONS
19	Risk factors and therapeutic coverage at 6â€¦years in patients with previous myocardial infarction: the CASTUO study. <i>Open Heart</i> , 2016, 3, e000368.	2.3	1
20	Polypill, el policomprimido cardiovascular: del concepto a la realidad en EspaÃ±a. <i>Revista Espanola De Cardiologia Suplementos</i> , 2015, 15, 19-24.	0.2	4
21	Altered FoF1 ATP synthase and susceptibility to mitochondrial permeability transition pore during ischaemia and reperfusion in aging cardiomyocytes. <i>Thrombosis and Haemostasis</i> , 2015, 113, 441-451.	3.4	46
22	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. <i>International Journal of Cardiology</i> , 2015, 201, S15-S23.	1.7	32
23	Global burden of CVD: focus on secondary prevention of cardiovascular disease. <i>International Journal of Cardiology</i> , 2015, 201, S1-S7.	1.7	219
24	The cardiovascular polypill: clinical data and ongoing studies. <i>International Journal of Cardiology</i> , 2015, 201, S8-S14.	1.7	27
25	Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis. <i>Heart</i> , 2014, 100, 1688-1695.	2.9	39
26	Defective sarcoplasmic reticulumâ€™mitochondria calcium exchange in aged mouse myocardium. <i>Cell Death and Disease</i> , 2014, 5, e1573-e1573.	6.3	85
27	Amyloid-Î² Increases Metallo- and Cysteine Protease Activities in Human Macrophages. <i>Journal of Vascular Research</i> , 2014, 51, 58-67.	1.4	6
28	Evolution of the Polypill Concept and Ongoing Clinical Trials. <i>Canadian Journal of Cardiology</i> , 2014, 30, 520-526.	1.7	21
29	Marfan Syndrome. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2014, 18, 260-271.	1.0	25
30	Promotion of Cardiovascular Health at Three Stages of Life: Never Too Soon, Never Too Late. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 731-737.	0.6	12
31	Polypill: Chimera or Reality?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 689-692.	0.6	1
32	A Polypill Strategy to Improve Adherence. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2071-2082.	2.8	290
33	A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 613-621.	2.8	74
34	Mechanisms of Stroke in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 5-15.	1.7	21
35	The Relationships Between Cardiovascular Disease and Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 41-57.	3.2	74
36	Promoting Cardiovascular Health Worldwide: Strategies, Challenges, and Opportunities. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 724-730.	0.6	21

#	ARTICLE	IF	CITATIONS
37	A very unusual cause of mechanical left ventricular outflow tract obstruction. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 44, 579-580.	1.4	0
38	Coronary Vasospasm Attributable to Fibromuscular Dysplasia. <i>Circulation: Heart Failure</i> , 2013, 6, e31-2.	3.9	4
39	Aiming at Strategies for a Complex Problem of Medical Nonadherence. <i>Global Heart</i> , 2013, 8, 263.	2.3	26
40	Anticoagulation during pregnancy in patients with a prosthetic heart valve. <i>Nature Reviews Cardiology</i> , 2012, 9, 415-424.	13.7	40
41	The influence of obesity on the assessment of carotid intima-media thickness. <i>Journal of Clinical Ultrasound</i> , 2012, 40, 479-485.	0.8	7
42	The links between complex coronary disease, cerebrovascular disease, and degenerative brain disease. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 99-105.	3.8	34
43	Are we ignoring the dilated thoracic aorta?. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 164-174.	3.8	12
44	Atrial fibrillation, stroke, and quality of life. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 140-150.	3.8	18
45	Cardiovascular defense challenges at the basic, clinical, and population levels. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 1-6.	3.8	18
46	Quantitative assessment of right ventricular function in pectus excavatum. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, e41-e42.	0.8	11
47	Dual-Source CT Coronary Angiogram in Heart Transplant Recipients in Comparison With Dobutamine Stress Echocardiography for Detection of Cardiac Allograft Vasculopathy. <i>Transplantation</i> , 2009, 87, 587-590.	1.0	24
48	Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 752-764.	0.6	26
49	Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension. <i>Hypertension</i> , 2007, 50, 977-983.	2.7	44
50	[18 F]-FDG PET and Localized Fibrous Mesothelioma. <i>Lung</i> , 2003, 181, 49-54.	3.3	34